Imperial scientists have developed developed a new method to make proteins form crystals using ‘smart materials’ that remember the shape and characteristics of the molecule - News release
Imperial College London News Release
Under embargo until
2000 hrs UK time
Monday 20 June 2011
Scientists have developed a new method to make proteins form crystals using ‘smart materials’ that remember the shape and characteristics of the molecule. The technique, reported today in Proceedings of the National Academy of Sciences, should assist research into new medicines by helping scientists work out the structure of drug targets.
- Naomi's Nucleant
- Department of Surgery and Cancer
- Faculty of Medicine
- Imperial Comprehensive Biomedical Research Centre
Related news stories:
The process of developing a new drug normally works by identifying a protein that is involved in the disease, then designing a molecule that will interact with the protein to stimulate or block its function. In order to do this, scientists need to know the structure of the protein that they are targeting.
A technique called X-ray crystallography can be used to analyse the arrangement of atoms within a crystal of protein, but getting a protein to come out of solution and form a crystal is a major obstacle. The number of proteins identified as potential drug targets is increasing exponentially as scientists make progress in the fields of genomics and proteomics, but with current methods, scientists have successfully obtained useful crystals for less than 20 per cent of proteins that have been tried.
Now researchers at Imperial College London and the University of Surrey have developed a more effective method for making proteins crystallise using materials called ‘molecularly imprinted polymers’ (MIPs). MIPs are compounds made up of small units that bind together around the outside of a molecule. When the molecule is extracted, it leaves a cavity that retains its shape and has a strong affinity for the target molecule.
This property makes MIPs ideal nucleants – substances that bind protein molecules and make it easier for them to come together to form crystals. Many substances have been used as nucleants before, but none are designed specifically to attract a particular protein.
“Proteins are very comfortable in solution,” said Professor Naomi Chayen, from the Department of Surgery and Cancer at Imperial College London, who led the research. “They need some convincing to come out and form a crystal.
“MIPs help this process by using the protein as a template for forming its own crystal. Once the first molecule or group of molecules is held in place, other molecules can arrange themselves around it and start to build a crystal.”
In the study, Professor Chayen and her colleagues found that six different MIPs induced crystallisation of nine proteins, yielding crystals in conditions that do not give crystals otherwise. They also tested whether MIPs would be effective at producing crystals from a series of preliminary trials for three target proteins for which scientists have not previously been able to obtain crystals of sufficient quality. The presence of MIPs gave rise to crystals in eight to 10 per cent of such trials, yielding valuable crystals that would have been missed using other known nucleants.
“Rational drug design depends on knowing the structure of the protein you’re trying to target, and getting good crystals is essential for studying the structure,” Professor Chayen said. “With MIPs we can get better crystals than we can with other methods, and also improve the probability of getting crystals from new proteins. This is a really significant innovation that could have a major impact on research leading to the development of new drugs.”
The research was funded by the Engineering and Physical Sciences Research Council and the European Commission.
For further information please contact:
Research Media Officer
Imperial College London
Tel: +44(0)20 7594 2198
Out of hours duty press officer: +44(0)7803 886 248
Notes to editors:
- Journal reference: Saridakis et al. ‘Protein crystallization facilitated by molecularly imprinted polymers’ Proceedings of the National Academy of Sciences, published online 20 June 2011.
- The Engineering and Physical Sciences Research Council (EPSRC) is the UK’s main agency for funding research in engineering and physical sciences. EPSRC invests around £800m a year in research and postgraduate training, to help the nation handle the next generation of technological change. The areas covered range from information technology to structural engineering, and mathematics to materials science. This research forms the basis for future economic development in the UK and improvements for everyone’s health, lifestyle and culture. EPSRC works alongside other Research Councils with responsibility for other areas of research. The Research Councils work collectively on issues of common concern via research Councils UK.
- About Imperial College London
Consistently rated amongst the world's best universities, Imperial College London is a science-based institution with a reputation for excellence in teaching and research that attracts 14,000 students and 6,000 staff of the highest international quality. Innovative research at the College explores the interface between science, medicine, engineering and business, delivering practical solutions that improve quality of life and the environment - underpinned by a dynamic enterprise culture.
Since its foundation in 1907, Imperial's contributions to society have included the discovery of penicillin, the development of holography and the foundations of fibre optics. This commitment to the application of research for the benefit of all con tinues today, with current focuses including interdisciplinary collaborations to improve global health, tackle climate change, develop sustainable sources of energy and address security challenges.
In 2007, Imperial College London and Imperial College Healthcare NHS Trust formed the UK's first Academic Hea lth Science Centre. This unique partnership aims to improve the quality of life of patients and populations by taking new discoveries and translating them into new therapies as quickly as possible.
Article text (excluding photos or graphics) available under an Attribution-NonCommercial-ShareAlike Creative Commons license.
Photos and graphics subject to third party copyright used with permission or © Imperial College London.
Communications and Public Affairs